Yvonne M.
Yvonne M. Goerlach-Doht, Rosengarten DE
Patent application number | Description | Published |
---|---|---|
20120029091 | METHOD OF CONTROLLING THE RELEASE OF AN ACTIVE INGREDIENT FROM A DOSAGE FORM - A method of controlling or adjusting release of an active ingredient from a dosage form comprising the active ingredient and a polysaccharide derivative has been found. The method comprises the steps of | 02-02-2012 |
20120187225 | PROCESS FOR DRY-GRINDING A POLYSACCHARIDE DERIVATIVE - In a process for producing a particulate polysaccharide derivative by dry-grinding a moist polysaccharide derivative the median length of the particles after dry-grinding is controlled by controlling the moisture content of the polysaccharide derivative prior to dry-grinding. Advantageously the median length of the particles after dry-grinding is adjusted to a first value by a first moisture content of the polysaccharide derivative prior to dry-grinding and is adjusted to a second value by a second moisture content. | 07-26-2012 |
20130112787 | PROCESS FOR DRY-GRINDING A POLYSACCHARIDE DERIVATIVE - In a process for producing a particulate polysaccharide derivative by dry-grinding a moist polysaccharide derivative, one or more of the properties selected from median diameter, median length, bulk density and dissolution rate is controlled by controlling the temperature of the polysaccharide derivative prior to thy-grinding. Advantageously one or more of the properties selected from median diameter, median length, bulk density and dissolution rate of the particles after thy-grinding is adjusted to a first value by a first temperature of the polysaccharide derivative prior to thy-grinding and is adjusted to a second value by a second temperature. | 05-09-2013 |
20140013999 | PROCESS FOR PRODUCING CELLULOSE DERIVATIVES OF HIGH BULK DENSITY, GOOD FLOWABILITY AND IMPROVED DISPERSIBILITY IN COLD WATER - A particulate cellulose derivative is obtained in a process of grinding and drying a moist cellulose derivative which comprises the steps of A) providing a cellulose derivative having a moisture content of from 60 to 95 percent, based on the total weight of the moist cellulose derivative, B) grinding and partially drying the moist cellulose derivative in a gas-swept impact mill; and C) contacting the ground and partially dried cellulose derivative with an additional amount of a drying gas outside the gas-swept impact mill. The obtained particulate cellulose derivative has a high untapped bulk density and a good flowability. | 01-16-2014 |
20140017319 | PROCESS FOR PRODUCING CELLULOSE DERIVATIVES OF HIGH BULK DENSITY AND GOOD FLOWABILITY - A particulate cellulose derivative is obtained in a process of grinding and drying a moist cellulose derivative which comprises the steps of A) providing a cellulose derivative having a moisture content of from 60 to 95 percent, based on the total weight of the moist cellulose derivative, B) grinding and partially drying the moist cellulose derivative in a gas-swept impact mill; and C) contacting the ground and partially dried cellulose derivative with an additional amount of a drying gas outside the gas-swept impact mill. The obtained particulate cellulose derivative has a high untapped bulk density and a good flowability. | 01-16-2014 |
20140018531 | PROCESS FOR REDUCING THE AMOUNT OF WATER-INSOLUBLE FIBERS IN A WATER-SOLUBLE CELLULOSE DERIVATIVE - The amount of water-insoluble fibers in a water-soluble cellulose derivative is reduced in a process comprising the steps of a) providing a water-soluble cellulose derivative having a residual amount of at least 20 ppm by weight of water-insoluble fibers in a 2 weight percent aqueous solution of the water-soluble cellulose derivative; b) mixing the water-soluble cellulose derivative of step a) with a liquid in a compounder to provide a moist water-soluble cellulose derivative having a temperature of at least 50 C and a moisture content of from 35 to 90 percent, based on the total weight of the moist cellulose derivative; and c) drying-grinding the mixture of step b) in a gas-swept impact mill to obtain a dried and ground cellulose derivative. | 01-16-2014 |
20150018420 | METHOD OF CONTROLLING THE RELEASE OF AN ACTIVE INGREDIENT FROM A DOSAGE FORM - A method of controlling or adjusting release of an active ingredient from a dosage form comprising the active ingredient and a polysaccharide derivative has been found. The method comprises the steps of | 01-15-2015 |
20150028526 | COMPOSITION FOR EXTRUSION-MOLDED CERAMIC BODIES COMPRISING A CELLULOSE DERIVATIVE OF CERTAIN MEDIAN PARTICLE LENGTH - A composition which is suitable for extrusion molding comprises a) a ceramic-forming material, and b) a cellulose derivative that has a median particle length of from 110 to 300 micrometers. Advantageously a cellulose ether is used that has been obtained by providing a moist cellulose derivative having a moisture content of from 35 to 90 percent, based on the total weight of the moist cellulose derivative, and drying-grinding the moist cellulose derivative in a gas-swept impact mill to a median particle length of from 110 to 300 micrometers. | 01-29-2015 |
Yvonne M. Janssen-Heininger, Charlotte, VT US
Patent application number | Description | Published |
---|---|---|
20100266566 | TREATMENTS INVOLVING GLUTAREDOXINS AND SIMILAR AGENTS - The present invention generally relates to treatments involving glutaredoxins. In one aspect, systems and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, airway inflammation or asthma. In some embodiments, a glutaredoxin may be used to treat a subject. Also provided in certain aspects of the present invention are kits for therapies involving glutaredoxins, methods for promoting such therapies, and the like. | 10-21-2010 |
20140140975 | TREATMENTS INVOLVING GLUTAREDOXINS AND SIMILAR AGENTS - The present invention generally relates to treatments involving glutaredoxins. In one aspect, systems and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, airway inflammation or asthma. In some embodiments, a glutaredoxin may be used to treat a subject. Also provided in certain aspects of the present invention are kits for therapies involving glutaredoxins, methods for promoting such therapies, and the like. | 05-22-2014 |
20150056633 | DETECTION OF GLUTATHIONYLATED PROTEINS - The present invention, in some aspects, relates to systems and methods for determining oxidized proteins, including glutathionylated proteins such as S-glutathionylated proteins. The systems and methods of the invention can be used in vitro (e.g., in cell or tissue culture) or in vivo, for example, to diagnose a person having an oxidative stress condition. For instance, in some cases, the invention can be used to spatially determine the location and/or concentration of oxidized proteins within cells and/or tissues (e.g., through visual detection). In one set of embodiments, a glutathionylated or otherwise oxidized moiety on a protein may be reacted with a detection entity, which may be, for example, fluorescent, radioactive, electron-dense, able to bind to a signaling entity or a binding partner in order to produce a signal, etc. As a specific example, a glutathionylated moiety on a glutathionylated protein may be reacted with an alkylating agent to form an alkylthio moiety; the alkylthio moiety may include a detection entity or otherwise be able to interact with a signaling entity. In some embodiments, other moieties on the protein may be altered or blocked before reaction of the protein with the detection entity. Such moieties on the protein may be, for instance, non-oxidized or non-glutathionylated moieties able to react with the detection entity. As a particular example, in a protein containing a glutathionylated moiety and non-glutathionylated thiol moieties, the thiol moieties may first be altered or blocked prior to reaction of the protein with the detection entity. Also provided in certain aspects of the present invention are kits for determining oxidized proteins, which may include components such as detection entities, alkylating agents, blocking agents, reducing agents, signaling entities, binding partners, antibodies, instructions, and the like. | 02-26-2015 |